Fig. 1
From: Antibody drug conjugates: hitting the mark in pancreatic cancer?
Structure of ADCs and specific components of ADCs in development for targeting pancreatic cancer
An ADC is composed of three main components: (1) A monoclonal antibody targeting a tumor specific antigen; (2) a linker molecule and (3) a cytotoxic payload that will kill the target cancer cell. Specific antigens, linkers and payloads being developed for the treatment of pancreatic cancer are listed
ADC: antibody drug conjugate;B7-H3: B7-homolog 3;CEA: carcinoembryonic antigen;EGFR: epidermal growth factor receptor;GCC: Guanylyl Cyclase C;HER2: human epidermal growth factor receptor 2;HER3: human epidermal growth factor receptor 3;ICAM-1: intercellular adhesion molecule 1;MMAE: monomethyl auristatin E;MMAF: monomethyl auristatin F;MUC1: mucin-1;SMCC: succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate;Trop2: trophoblast antigen 2.